+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cardiac toxicity after anthracycline chemotherapy in childhood



Cardiac toxicity after anthracycline chemotherapy in childhood



Herz 25(7): 676-688



The clinical use of anthracyclines, a family of chemotherapeutic agents with efficacy against many solid tumors and leukemias is limited by unique cumulative dose-limiting cardiotoxicity. Overt heart failure occurs in 4.5% to 7% of patients treated with anthracyclines and the incidence of cardiac function abnormalities increases with the time. Anthracycline-induced congestive heart failure is usually due to permanent changes in the myocardium, changes most consistent with the contractile failure of cardiomyopathy. Although the causes of anthracycline-induced cardiotoxicity are probably many, a large body of evidence points to free-radical-mediated myocyte damage. The risk of developing cardiac heart failure is modified by the presence of certain risk factors that reduce cardiac tolerance to anthracyclines. Age and female gender seem to have an important role in the anthracycline cardiotoxicity. This cardiotoxicity can be divided, on the base of when it started, into acute, subacute and progressive late, chronic form. Various invasive and non-invasive methods have been used to measure the extent of cardiac damage done. Depending on the sensitivity of the method employed, the proportion of hearts found to be damaged has varied widely. Attempts to ameliorate anthracycline cardiotoxicity have been directed toward: 1. decreasing myocardial concentrations of anthracyclines and their metabolites, 2. developing less cardiotoxic analogous, and 3. concurrently administering cardioprotectants to attenuate the effects of anthracyclines on the heart. Much progress has been made in terms of monitoring of clinical and subclinical anthracycline cardiotoxicity, finding alternative schedules, introducing special carriers of anthracyclines and using cardioprotecting agents. It is hoped that with all these effects and with results of ongoing and future trials, we will be able to reduce further or even eliminate anthracycline cardiotoxicity.

(PDF emailed within 0-6 h: $19.90)

Accession: 010277364

Download citation: RISBibTeXText

DOI: 10.1007/pl00001982


Related references

Cardiac toxicity after anthracycline chemotherapy in childhood. Herz 25(7): 676-688, 2001

Evaluation of late cardiac toxicity of anthracycline in childhood. Minerva Pediatrica 50(4): 111-119, 1998

Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors. Journal of Pediatric Hematology/Oncology 32(5): 411-415, 2010

Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer. Cancer 115(22): 5296-5308, 2009

Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. Journal of Clinical Oncology 25(24): 3635-3643, 2007

Gender and age do not alter actuarial incidence of cardiac dysfunction following anthracycline chemotherapy of childhood malignancy. Pediatric Research 45(4 PART 2): 30A, 1999

Should non-anthracycline-based chemotherapy (Non-A) substitute anthracycline-based (A) when combined with taxanes (T) as 1st-line chemotherapy (CT) for advanced breast cancer (ABC)? Meta-analysis of randomized clinical trials (RCTs) balancing efficacy and toxicity. Journal of Clinical Oncology 26(15_suppl): 1087-1087, 2016

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. Breast 29: 153-159, 2017

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Annals of Oncology 24(9): 2278-2284, 2014

Carcinogenicity of acrylonitrile and evaluation of approaches to pathogenetic correction of acrylate toxicity and antitumorigenic anthracycline doxorubicin toxicity during chemotherapy. Vestnik Rossiiskoi Akademii Meditsinskikh Nauk 2013(2): 63-66, 2013

Late cardiotoxic effects of anthracycline chemotherapy in childhood malignancies. Jpma. Journal of the Pakistan Medical Association 58(12): 683-687, 2009

A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy. Nuclear Medicine Communications 33(1): 51-59, 2012

Cardio toxicity of anthracycline antibiotic in childhood leukemia and other malignancies. Mie Medical Journal 30(3): 305-310, 1981

Left ventricular systolic and diastolic function after anthracycline chemotherapy in childhood. Clinical Cardiology 24(10): 663-669, 2001

Mechanisms of anthracycline cardiac toxicity. Abstracts of Papers American Chemical Society 205(1-2): CARB 50, 1993